Cover Image

Intracranial Efficacy of Pyrotinib and Capecitabine Combination Therapy in HER2-Positive Breast Cancer with Brain Metastases

Congcong Wang,1,&ast; Jinyu Xiang,1,&ast; Qingyu Zhang,1 Jing Li,1 Yanqing Liu,2 Jiannan Liu1 1Department of Oncology, The Affiliated Yantai Yuhuangding Hospital of Qingdao University, Yantai, Shangdong, 264000, People's Republic of China; 2Department Brest Surgery, The Affiliated Yanta...

Full description

Saved in:

Bibliographic Details
Main Authors:	Wang C (Author), Xiang J (Author), Zhang Q (Author), Li J (Author), Liu Y (Author), Liu J (Author)
Format:	Book
Published:	Dove Medical Press, 2024-03-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Survival benefit and biomarker analysis of pyrotinib or pyrotinib plus capecitabine for patients with HER2-positive metastatic breast cancer: a pooled analysis of two phase I studies
by: Xiuwen Guan, et al.
Published: (2023)

A validated UPLC-MS/MS method for quantification of pyrotinib and population pharmacokinetic study of pyrotinib in HER2-positive breast cancer patients
by: Yunfang Zhu, et al.
Published: (2024)

The Clinical Efficacy and Safety of Neratinib in Combination with Capecitabine for the Treatment of Adult Patients with Advanced or Metastatic HER2-Positive Breast Cancer
by: Chilà G, et al.
Published: (2021)

Treatment of HER2-Positive Breast Cancer with Brain Metastases Using Anlotinib and Trastuzumab Deruxtecan: A Case Report
by: Chen Y, et al.
Published: (2024)

Real-world efficacy and safety of pyrotinib in patients with HER2-positive metastatic breast cancer: A prospective real-world study
by: Qiongwen Zhang, et al.
Published: (2023)

The Efficacy of Pyrotinib as a Third- or Higher-Line Treatment in HER2-Positive Metastatic Breast Cancer Patients Exposed to Lapatinib Compared to Lapatinib-Naive Patients: A Real-World Study
by: D. J Ouyang, et al.
Published: (2021)

Current approaches to the treatment of HER2‑positive breast cancer with brain metastases
by: T. Yu. Semiglazova, et al.
Published: (2021)

Case report: Pyrotinib and tegafur combined with radiotherapy achieved notable response in HER2-amplified rectal cancer with multiple metastases after multiline treatments
by: Peng Huang, et al.
Published: (2024)

Role of targeted therapy in the treatment of HER-2-positive breast cancer brain metastases
by: G. A. Dashyan, et al.
Published: (2016)

Trastuzumab-functionalized SK-BR-3 cell membrane-wrapped mesoporous silica nanoparticles loaded with pyrotinib for the targeted therapy of HER-2-positive breast cancer
by: Xing Liu, et al.
Published: (2024)

Pharmacoeconomic analysis of trastuzumab emtanzine comparing to lapatinib + capecitabine in pa-tients with HER2+ breast cancer and central nervous system metastases
by: A. S. Kolbin, et al.
Published: (2018)

The efficacy and potential mechanisms of pyrotinib in targeting EGFR and HER2 in advanced oral squamous cell carcinoma
by: Liang Zhou, et al.
Published: (2024)

Comparison of the efficacy and survival analysis of neoadjuvant chemotherapy for Her-2-positive breast cancer
by: Li S, et al.
Published: (2018)

Hepatic toxicity in HER-2(+) breast cancer patient under treatment with capecitabine and lapatinib
by: Elia Romero Carreño, et al.
Published: (2016)

Multiple Administrations of Itraconazole Increase Plasma Exposure to Pyrotinib in Chinese Healthy Adults
by: Liu Y, et al.
Published: (2021)

Calcium Electroporation for Management of Cutaneous Metastases in HER2-Positive Breast Cancer: A Case Report
by: Katrine Borres Jensen, et al.
Published: (2022)

Intracranial Metastases Tend to Be Overt and Predict Poor Prognosis in Children With Neuroblastoma
by: Ying Liu, et al.
Published: (2021)

Clinical features of brain metastases in breast cancer: an implication for hippocampal-sparing whole-brain radiation therapy
by: Wu S, et al.
Published: (2016)

Fructus mume Extracts Alleviate Diarrhea in Breast Cancer Patients Receiving the Combination Therapy of Lapatinib and Capecitabine
by: Hua Xing, et al.
Published: (2018)

A pathological complete response to capecitabine plus oxaliplatin regimen combined with tislelizumab in advanced gastric cancer with liver metastases: A case report
by: Li-Ping Sheng, et al.
Published: (2024)

The Clinical Value of Chemotherapy Combined With Capecitabine in Triple-Negative Breast Cancer-A Meta-Analysis
by: Zilin Zhang, et al.
Published: (2021)

Prediction of pyrotinib exposure based on physiologically-based pharmacokinetic model and endogenous biomarker
by: Miao Zhang, et al.
Published: (2022)

Combined Effect of Sertraline and Capecitabine on Breast Cancer Cell Lines In Vitro and In Silico Evidence for Synergistic Interaction
by: Serap Ozkaya Gul, et al.
Published: (2024)

An update of pharmacoeconomic analysis of trastuzumab emtanzine in patients with HER2+ breast cancer and central nervous system metastases
by: A. S. Kolbin, et al.
Published: (2019)

Differential effects of ketoconazole, fluconazole, and itraconazole on the pharmacokinetics of pyrotinib in vitro and in vivo
by: Li Wang, et al.
Published: (2022)

Anti-transcriptional intermediary factor-1γ antibody-positive dermatomyositis in a patient with triple-negative breast cancer treated with adjuvant capecitabine
by: Alaina J. Kessler, MD, MPH, et al.
Published: (2023)

Comparative efficacy and safety of Chinese medicine injections combined with capecitabine and oxaliplatin chemotherapies in treatment of colorectal cancer: A bayesian network meta-analysis
by: Shuzhen Liu, et al.
Published: (2022)

Neratinib for HER2-positive breast cancer with an overlooked option
by: Liting Guo, et al.
Published: (2023)

Effect of capecitabine on breast cancer patients with different estrogen receptor status
by: Gang Xu, et al.
Published: (2020)

Effects of Shenling Baizhu powder on pyrotinib-induced diarrhea: analysis of gut microbiota, metabonomics, and network pharmacology
by: Jingjiang Lai, et al.
Published: (2022)

Clinical predictive score of intracranial hemorrhage in mild traumatic brain injury
by: Yuksen C, et al.
Published: (2018)

Safety and efficacy of the addition of pertuzumab to T-DM1 ± taxane in patients with HER2-positive, locally advanced or metastatic breast cancer: a pooled analysis
by: Zhang J, et al.
Published: (2017)

Educational Case: HER-2 Positive Breast Cancer
by: Julia Jennings MD, et al.
Published: (2021)

Cost of illness of HER2-positive and metastatic and recurrent HER2-positive breast cancer - a Danish register-based study from 2005 to 2016
by: M. Spanggaard, et al.
Published: (2022)

Targeting autophagy: A promising approach for the treatment of breast cancer brain metastases
by: Steffan T. Nawrocki, et al.
Published: (2024)

Case report: outcome of anlotinib treatment in breast cancer patient with brain metastases
by: Qiongwen Zhang, et al.
Published: (2024)

Exploring The Impact of Capecitabine Treatment on Hormonal and Biochemical Markers in Women with Breast Cancer
by: Raaid Fadhl Abbas Masoudi, et al.
Published: (2023)

[Translated article] Capecitabine-Induced Focal Acral Pigmentation
by: M. Álvarez-Salafranca, et al.
Published: (2024)

Baseline Lymphopenia: A Predictor Of Poor Outcomes In HER2 positive Metastatic Breast Cancer Treated With Trastuzumab
by: Che YQ, et al.
Published: (2019)

A Case Report of Zosteriform Cutaneous Metastases from Breast Carcinoma
by: Xu L, et al.
Published: (2024)